Unknown

Dataset Information

0

Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.

ABSTRACT: We report herein the design and synthesis of a series of potent and selective GPR119 agonists. Our objective was to develop a GPR119 agonist with properties that were suitable for fixed-dose combination with a DPP4 inhibitor. Starting from a phenoxy analogue (1), medicinal chemistry efforts directed toward reducing half-life and increasing solubility led to the synthesis of a series of benzyloxy analogues. Compound 28 was chosen for further profiling because of its favorable physicochemical properties and excellent GPR119 potency across species. This compound exhibited a clean off-target profile in counterscreens and good in vivo efficacy in mouse oGTT.

SUBMITTER: Liu P 

PROVIDER: S-EPMC4538435 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

We report herein the design and synthesis of a series of potent and selective GPR119 agonists. Our objective was to develop a GPR119 agonist with properties that were suitable for fixed-dose combination with a DPP4 inhibitor. Starting from a phenoxy analogue (1), medicinal chemistry efforts directed toward reducing half-life and increasing solubility led to the synthesis of a series of benzyloxy analogues. Compound 28 was chosen for further profiling because of its favorable physicochemical prop  ...[more]

Similar Datasets

Unknown Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
| S-EPMC4027368 | biostudies-literature
Unknown Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.
| S-EPMC4753552 | biostudies-literature
Unknown Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS.
| S-EPMC4017978 | biostudies-literature
Unknown Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists.
| S-EPMC4007837 | biostudies-other
Unknown Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes.
| S-EPMC5430397 | biostudies-literature
Unknown Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats.
| S-EPMC6696947 | biostudies-literature
Unknown Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice.
| S-EPMC3501123 | biostudies-literature
Unknown Program ACTIVE II: Design and Methods for a Multi-Center Community-Based Depression Treatment for Rural and Urban Adults with Type 2 Diabetes.
| S-EPMC4974010 | biostudies-literature
Unknown GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
| S-EPMC2268073 | biostudies-literature
Unknown Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.
| S-EPMC4027509 | biostudies-literature